Jew Therapeutics announced that its cellular immunotherapy drugs have successfully benefited 300 patients

SHANGHAI, Nov.
9, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent innovative biotechnology company focused on developing, manufacturing and commercializing cellular immunotherapy products, announced that as of November 8, 2022, its cellular immunotherapy drugs (including marketed products and drug candidates) have successfully completed the infusion therapy (both clinical research and commercialization stages) for 300 patients.
There is hope
for a cure for these patients and their families.

WuXi JW has successfully built a world-class cell immunotherapy technology and product development platform, as well as a product pipeline covering hematological and solid tumors, and has carried out 9 clinical studies
for hematological and solid tumors.
As JW Therapeutics' first product and a Class 1 new CAR-T product, Tenoda ^® (relmacel injection) achieved the first patient infusion treatment in December 2017 and was approved by the National Medical Products Administration of China in September 2021
.
In addition, JW Therapeutics has initiated clinical studies
for solid tumors such as advanced hepatocellular carcinoma this year.

Yiping Li, co-founder, chairman and CEO of JW Therapeutics, said, "Serving patients is JW Therapeutics' original intention
.
Thank you to regulators, researchers, healthcare workers, business partners and others for working with us to serve patients
.
We will continue to introduce and develop more cutting-edge technologies, advance product pipelines, reduce production costs, and bring hope for healing to every patient
.
"